• A
  • A
  • A
日本語 Help
Science and technology information site for articles, patents, researchers information, etc.

Co-authoring Researcher

Co-inventing Researcher

Researcher similar to the Researcher

Article similar to the Researcher

Patent similar to the Researcher

Research Project similar to the Researcher

Article(J-GLOBAL estimation)

Patent(J-GLOBAL estimation)

Rchr
J-GLOBAL ID:201801017812008437   Update date: Dec. 21, 2024

Nakano Kosuke

ナカノ コウスケ | Nakano Kosuke
Clips
Affiliation and department:
Research field  (1): Urology
Research keywords  (1): 泌尿器科
Research theme for competitive and other funds  (3):
  • 2021 - 2022 Overcoming heterogeneity with circulating tumor DNA in urothelial carcinoma and establishing personalized medicine
  • 2019 - 2021 AI-based diagnosis of urothelial carcinoma using plasma cell-free DNA fragments and clinical application of the genetic mutation
  • 2017 - 2019 Comprehensive analysis for castration-resistant prostate cancer-specific proteins in serum extracellular vesicles.
Papers (74):
  • Akinaru Yamamoto, Atsunari Kawashima, Toshihiro Uemura, Kosuke Nakano, Makoto Matsushita, Yu Ishizuya, Kentaro Jingushi, Hiroaki Hase, Kotoe Katayama, Rui Yamaguchi, et al. A novel mouse model of upper tract urothelial carcinoma highlights the impact of dietary intervention on gut microbiota and carcinogenesis prevention despite carcinogen exposure. International journal of cancer. 2024
  • Gaku Yamamichi, Taigo Kato, Noriaki Arakawa, Yoko Ino, Takeshi Ujike, Kosuke Nakano, Yoko Koh, Yuichi Motoyama, Hidetatsu Outani, Shohei Myoba, et al. GDF15 propeptide promotes bone metastasis of castration-resistant prostate cancer by augmenting the bone microenvironment. Biomarker research. 2024. 12. 1. 147-147
  • 山本 致之, 河嶋 厚成, 長谷 拓明, 宮崎 陽平, 堀部 祐輝, 谷 優, Nesrine Sassi, 植村 俊彦, 山本 顕生, 山道 岳, et al. 尿路上皮癌におけるRNA修飾クラスターの意味(Implications of RNA modification clusters in urothelial carcinoma). 日本癌学会総会記事. 2023. 82回. 546-546
  • Soichi Matsumura, Taigo Kato, Yuma Kujime, Hiroaki Kitakaze, Kosuke Nakano, Sachiko Hongo, Iwao Yoshioka, Masayoshi Okumi, Norio Nonomura, Shingo Takada. Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab. BMC urology. 2023. 23. 1. 107-107
  • Taigo Kato, Satoru Yumiba, Wataru Nakata, Kosuke Nakano, Akira Nagahara, Kyosuke Matsuzaki, Yujiro Hayashi, Koji Hatano, Atsunari Kawashima, Tetsuya Takao, et al. A comparative study on nivolumab and axitinib as secondary treatment in patients with metastatic renal cell carcinoma: A multi-institutional retrospective study in Japan. International journal of urology : official journal of the Japanese Urological Association. 2022
more...
MISC (89):
  • 山本顕生, 河嶋厚成, 奥田洋平, 岡利樹, 植村俊彦, 中野剛佑, 松下慎, 石津谷祐, 山本致之, 加藤大悟, et al. Establishment of a novel mouse model in carcinogenesis of upper tract urothelial carcinoma. 日本泌尿器科学会総会(Web). 2023. 110th
  • Taigo Kato, Eisuke Tomiyama, Yoko Koh, Makoto Matsushita, Yujiro Hayashi, Kosuke Nakano, Yu Ishizuya, Cong Wang, Koji Hatano, Atsunari Kawashima, et al. T cell receptor sequencing predict early response for immune-check point inhibitors in urological cancer. CANCER SCIENCE. 2021. 112. 398-398
  • Taigo Kato, Eisuke Tomiyama, Yoko Koh, Makoto Matsushita, Kosuke Nakano, Yujiro Hayashi, Cong Wang, Yu Ishizuya, Koji Hatano, Takeshi Ujike, et al. IDENTIFICATION OF EARLY PREDICTIVE BIOMARKER FOR IMMUNE CHECKPOINT INHIBITORS BY T CELL RECEPTOR REPERTOIRE ANALYSIS IN ADVANCED KIDNEY CANCER PATIENTS. JOURNAL OF UROLOGY. 2020. 203. E234-E234
  • 松下慎, 藤田和利, 林拓自, 冨山栄輔, 洪陽子, 中野剛佑, 林裕次郎, 加藤大悟, 加藤大悟, 波多野浩士, et al. 高脂肪食摂取前立腺癌モデルマウスの前立腺組織の網羅的遺伝子発現解析による,高脂肪食が促進する癌増殖のメカニズムの解明. 日本アンドロロジー学会総会記事. 2020. 39th
  • 林裕次郎, 藤田和利, 冨山栄輔, 松下慎, 洪陽子, 中野剛佑, 加藤大悟, 加藤大悟, 波多野浩士, 河嶋厚成, et al. TERT promoter mutation in no malignant urothelium is associated with bladder recurrence in non-muscle invasive bladder cancer patients. 日本泌尿器科学会総会(Web). 2020. 108th
more...
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page